The conference’s abstract drop features ASC4First in its plenary session.

Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.

An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.

Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?

Abstract titles reveal some of ASCO’s key datasets.

After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.

Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.

One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.